Navigation Links
Amgen to Present at the Leerink Swann Global Healthcare Conference
Date:2/14/2012

THOUSAND OAKS, Calif., Feb. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time  on Thursday, Feb. 16, 2012, at the Waldorf Astoria Hotel in New York City.  Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 

 

 

 


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen to Acquire Micromet
2. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
3. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen Announces 2012 First Quarter Dividend
6. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
7. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
8. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
9. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
10. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
11. Amgen Announces 2011 Fourth Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/7/2020)... BOSTON (PRWEB) , ... July 06, 2020 , ... ... Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of ... Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples ...
(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... ... are racing to develop a vaccine or drug treatment. In an effort to ... has publicly released the world’s largest imaging dataset portraying therapeutic compound effects ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... now offering an Amniosomes special offer. This includes buy three, get the fourth ... call (888) 568-6909. , Amniotic derived exosomes, known as exosomes, have been a ...
Breaking Biology Technology:
(Date:7/2/2020)... ... July 01, 2020 , ... ... phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute ... Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research ...
(Date:7/1/2020)... , ... July 01, 2020 , ... ... awareness and solutions for glioblastoma—the most common and aggressive adult brain cancer—announced today ... JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives and overall ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics ... inhibitor, in hospitalized patients with severe COVID-19. This is the first study of ...
Breaking Biology News(10 mins):